Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19085527 | 0.77 | TSHR (0.52) | DNM1LMNATSHRMEN1KMT2A | |
| SCHEMBL9883738 | 0.75 | LMNA (0.43) | LMNATSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL27010002 | 0.75 | PAOX (0.41) | LMNAALDH1A1 | |
| SCHEMBL24262297 | 0.74 | DNM1 (0.32) | DNM1LMNA | |
| SCHEMBL24477430 | 0.73 | FAAH (0.53) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL25634872 | 0.73 | EPHX2 (0.36) | MAPTDNM1LMNA | |
| SCHEMBL23324950 | 0.72 | CHRNB2 (0.38) | LMNAALDH1A1 | |
| SCHEMBL5508427 | 0.72 | TDP1 (0.36) | ALDH1A1 | |
| SCHEMBL8396924 | 0.71 | TSHR (0.43) | MAPTLMNATSHRALDH1A1 | |
| SCHEMBL24811024 | 0.71 | LMNA (0.39) | DNM1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919852-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2021-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919852-B2 | Immunomodulator compounds | IL2, FCGRT, IFNG | MAPT 4818/4885DNM1 3810/4885LMNA 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.